- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001158
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
March 4, 2008 updated by: National Cancer Institute (NCI)
The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer.
In vitro assays and in vivo skin tests and immunization with antigens will be utilized.
Study Overview
Status
Completed
Conditions
Detailed Description
The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer.
In vitro assays and in vivo skin tests and immunization with antigens will be utilized.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Patients will be studied if a disorder of the immune system is suspected.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 1977
Study Completion
March 1, 2000
Study Registration Dates
First Submitted
November 3, 1999
First Submitted That Met QC Criteria
December 9, 2002
First Posted (Estimate)
December 10, 2002
Study Record Updates
Last Update Posted (Estimate)
March 5, 2008
Last Update Submitted That Met QC Criteria
March 4, 2008
Last Verified
April 1, 1999
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 770066
- 77-C-0066
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
Peking University First HospitalRecruitingBreast Neoplasms、Lung Neoplasms、Pancreatic NeoplasmsChina
-
Hospices Civils de LyonNot yet recruiting
-
GlaxoSmithKlineCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ain Shams UniversityNot yet recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Medical College of WisconsinM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Chicago and other collaboratorsRecruiting
-
GlaxoSmithKlineRecruitingNeoplasms, ColonSpain, Belgium, Japan, Italy, United Kingdom, Switzerland